BioMarin Pharmaceutical Inc. Stock price

Equities

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
87.14 USD +1.00% Intraday chart for BioMarin Pharmaceutical Inc. -4.49% -9.62%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 2.77B Sales 2025 * 3.15B Capitalization 16.44B
Net income 2024 * 302M Net income 2025 * 497M EV / Sales 2024 * 5.59 x
Net cash position 2024 * 972M Net cash position 2025 * 1.24B EV / Sales 2025 * 4.82 x
P/E ratio 2024 *
54.3 x
P/E ratio 2025 *
32.9 x
Employees 3,401
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.26%
More Fundamentals * Assessed data
Dynamic Chart
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update DJ
BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies RE
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme DJ
BioMarin Pharma gets DOJ subpoena on certain drug testing programs RE
Wedbush Adjusts BioMarin Pharmaceutical's PT to $80 From $78, Keeps Neutral Rating; Continues to See Limited Upside MT
Transcript : BioMarin Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 22, 2024
BioMarin Pharmaceutical Q4 Adjusted Earnings, Revenue Rise, 2024 Outlook Set -- Shares Decline After Hours MT
BioMarin Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q4 EPS $0.49 MT
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q4 Revenue $646.2M MT
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024 CI
BioMarin Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BofA Securities Cuts BioMarin Pharmaceutical Price Target to $150 From $170, Maintains Buy Rating MT
Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024 CI
Biomarin Pharmaceutical Insider Sold Shares Worth $1,945,700, According to a Recent SEC Filing MT
More news
1 day+1.00%
1 week-4.49%
Current month+1.00%
1 month-1.80%
3 months-5.71%
6 months-6.33%
Current year-9.62%
More quotes
1 week
85.88
Extreme 85.88
92.16
1 month
85.60
Extreme 85.6
94.15
Current year
85.60
Extreme 85.6
99.25
1 year
76.02
Extreme 76.02
101.48
3 years
70.73
Extreme 70.73
117.77
5 years
62.88
Extreme 62.88
131.95
10 years
55.04
Extreme 55.04
151.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 Nov. 30
Director of Finance/CFO 50 02-11-30
Chief Tech/Sci/R&D Officer - 20-10-04
Members of the board TitleAgeSince
Director/Board Member 71 16-01-03
Director/Board Member 70 05-05-15
Chairman 65 06-12-13
More insiders
Date Price Change Volume
24-03-01 87.14 +1.00% 1,927,867
24-02-29 86.28 -2.40% 2,604,480
24-02-28 88.4 -2.51% 1,172,830
24-02-27 90.68 +0.64% 1,249,150
24-02-26 90.1 -1.25% 1,470,158

Delayed Quote Nasdaq, March 01, 2024 at 04:00 pm EST

More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company's clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
87.14 USD
Average target price
110.1 USD
Spread / Average Target
+26.39%
Consensus
  1. Stock
  2. Equities
  3. Stock BioMarin Pharmaceutical Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW